Treatment of squamous cell carcinoma of the esophagus synchronously associated with head and neck cancer

Masaru Morita; Akinori Egashira; Yu Nakaji; Masaki Kagawa; Masahiko Sugiyama; Daisuke Yoshida; Mitsuhiko Ota; Masahiko Ikebe; Muneyuki Masuda; Yojiro Inoue; Naonobu Kunitake; Yasushi Toh

doi:10.21873/invivo.11146

Treatment of squamous cell carcinoma of the esophagus synchronously associated with head and neck cancer

Masaru Morita, Akinori Egashira, Yu Nakaji, Masaki Kagawa, Masahiko Sugiyama, Daisuke Yoshida, Mitsuhiko Ota, Masahiko Ikebe, Muneyuki Masuda, Yojiro Inoue, Naonobu Kunitake, Yasushi Toh

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Background/Aim: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC). Patients and Methods: Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection. Results: Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58%) and 19 patients with HNC (50%). The five-year survival rate was 44%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70%. Conclusion: The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options.

Original language	English
Pages (from-to)	909-916
Number of pages	8
Journal	In Vivo
Volume	31
Issue number	5
DOIs	https://doi.org/10.21873/invivo.11146
Publication status	Published - Sept 1 2017
Externally published	Yes

All Science Journal Classification (ASJC) codes

Biochemistry, Genetics and Molecular Biology(all)
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/invivo.11146

Cite this

@article{2c6385129756403fbf666d248ae7d70d,

title = "Treatment of squamous cell carcinoma of the esophagus synchronously associated with head and neck cancer",

abstract = "Background/Aim: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC). Patients and Methods: Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection. Results: Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58%) and 19 patients with HNC (50%). The five-year survival rate was 44%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70%. Conclusion: The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options.",

author = "Masaru Morita and Akinori Egashira and Yu Nakaji and Masaki Kagawa and Masahiko Sugiyama and Daisuke Yoshida and Mitsuhiko Ota and Masahiko Ikebe and Muneyuki Masuda and Yojiro Inoue and Naonobu Kunitake and Yasushi Toh",

note = "Funding Information: This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sport, Science and Technology of Japan and the Fujii Setsuro Memorial Foundation.",

year = "2017",

month = sep,

day = "1",

doi = "10.21873/invivo.11146",

language = "English",

volume = "31",

pages = "909--916",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "5",

}

TY - JOUR

T1 - Treatment of squamous cell carcinoma of the esophagus synchronously associated with head and neck cancer

AU - Morita, Masaru

AU - Egashira, Akinori

AU - Nakaji, Yu

AU - Kagawa, Masaki

AU - Sugiyama, Masahiko

AU - Yoshida, Daisuke

AU - Ota, Mitsuhiko

AU - Ikebe, Masahiko

AU - Masuda, Muneyuki

AU - Inoue, Yojiro

AU - Kunitake, Naonobu

AU - Toh, Yasushi

N1 - Funding Information: This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sport, Science and Technology of Japan and the Fujii Setsuro Memorial Foundation.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background/Aim: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC). Patients and Methods: Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection. Results: Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58%) and 19 patients with HNC (50%). The five-year survival rate was 44%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70%. Conclusion: The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options.

AB - Background/Aim: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC). Patients and Methods: Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection. Results: Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58%) and 19 patients with HNC (50%). The five-year survival rate was 44%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70%. Conclusion: The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options.

UR - http://www.scopus.com/inward/record.url?scp=85029509172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029509172&partnerID=8YFLogxK

U2 - 10.21873/invivo.11146

DO - 10.21873/invivo.11146

M3 - Article

C2 - 28882958

AN - SCOPUS:85029509172

SN - 0258-851X

VL - 31

SP - 909

EP - 916

JO - In Vivo

JF - In Vivo

IS - 5

ER -

Treatment of squamous cell carcinoma of the esophagus synchronously associated with head and neck cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this